Discovery and Evaluation of Inhibitors of Human Ceramidase
Jeremiah M. Draper1, Zuping Xia1, Ryan A. Smith2, Yan Zhuang2, Wenxue Wang1, and Charles D. Smith1,2

Abstract
The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a critical role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation. Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation. Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs. In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small molecule library and describe the synthesis of a more potent analogue (Ceranib-2). In a cell-based assay, both compounds were found to inhibit cellular ceramidase activity toward an exogenous ceramide analogue, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death. In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity. These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity. Mol Cancer Ther; 10(11); 2052–61. ©2011 AACR.

Introduction
The mechanisms and effects of the interconversion of sphingolipids have been the subject of a growing body of scientific investigation (reviewed in refs. 1–7). In the sphingolipid metabolic pathway, ceramide is produced by the hydrolysis of sphingomyelin in response to several growth stimulatory and/or inflammatory signals, and the accumulation of ceramide induces apoptosis in tumor cells without disrupting quiescent normal cells (8–11). In turn, ceramide can be hydrolyzed by the action of ceramidase enzymes to produce sphingosine, which is phosphorylated by sphingosine kinases (SK1 and SK2) to produce sphingosine-1-phosphate. It has been hypothesized that a critical balance, that is, a ceramide/sphingo-

Authors' Affiliations: 1Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina; and 2Apogee Biotechnology Corporation, Hummelstown, Pennsylvania

Corresponding Author: Charles D. Smith, Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, 280 Calhoun Street, MSC140, Charleston, SC 29425. Phone: 843-792-3420 Fax: 843-792-9988 E-mail: smithchd@musc.edu
doi: 10.1158/1535-7163.MCT-11-0365©2011 American Association for Cancer Research.
pharmaceutical shortcomings that will likely hinder their development as clinically viable therapeutics. Most importantly, the current ceramidase inhibitors are typically ceramide analogues containing long-chain alkyl moieties. Highly hydrophobic compounds such as these tend to have poor pharmacologic properties due to binding with albumin, resulting in poor bioavailability. Thus, there is a need to identify "drug-like" small molecule inhibitors of ceramidases that can be developed into anticancer agents.

In this study, we sought to identify novel small molecule inhibitors of ceramidase activity with favorable pharmacologic properties that can be further developed into anticancer therapeutics. We herein show that our newly identified compounds inhibit the hydrolysis of an exogenous ceramide substrate and induce the accumulation of ceramide while decreasing intracellular levels of sphingosine and S1P. In addition, these new ceramidase inhibitors are antiproliferative and proapoptotic, and have in vitro antitumor activity.

Materials and Methods

Materials

Unless otherwise noted, all chemicals and reagents were purchased from Sigma-Aldrich. The chemical library was purchased from ChemBridge Corporation and compounds were provided as solutions at a concentration of 5849350. MALDI-TOF MS spectra was obtained on a Voyager RP mass spectrometer. Solvents were dried and redistilled before use, and reactions requiring anhydrous conditions were conducted under an atmosphere of nitrogen. Ceranib-2 was prepared by a 2-step synthesis (Fig. 1B) as follows: (i) A solution of 1.97 g (0.01 mol) of o-aminobenzenophene (1) and 2.6 g (0.02 mol) of acetylacetone (2) was heated under reflux for 4 hours. The reaction mixture was cooled and poured slowly, with stirring, into an ice-cold solution of 40 mL of water. The resulting suspension was allowed to stand in an ice bath until the gummy precipitate had hardened, after which the crude product was collected, washed with water, and recrystallized from aqueous ethanol to give 1.82 g of 3-acetyl-4-phenyl-1H-quinolin-2-one as off-white needles, with a melting point of 256°C to 258°C. Recrystallization from aqueous ethanol raised the melting point to 260°C to 261°C. Spectral data for 3: 1H NMR δ 8.34 (s, 3H, COCH3), 7.16–7.19 (t, J = 7.5 Hz, 1H, Ar-H), 7.29–7.31 (d, J = 10 Hz, 1H, Ar-H), 7.36–7.38 (d, J = 10 Hz, 2H, Ar-H), 7.48–7.53 (m, 4H, Ar-H), 7.56–7.59 (t, J = 7.5 Hz, 1H, Ar-H), 12.61 (s, 1H, NH);13C NMR δ 51.76, 116.45, 119.93, 123.0, 127.75, 128.61, 129.06, 131.46, 132.88, 134.31, 138.23, 149.03, 161.43, 201.81; MS m/z (relative intensity) 264.41 (M⁺ + 1, 100), 265.41(30). (ii) NaOH powder (12 mmol) was added to a 50 mL round-bottom flask containing a 20 mL EtOH plus 10 mL CH2Cl2 solution of 3 and 4-methoxybenzaldehyde (4, 4 mmol) under N2 and stirred at 25°C overnight. The reaction mixture was acidified to pH 3, washed 3 times with water (3 × 10 mL), and filtered to give the crude product 3-[3-(4-methoxyphenyl)acryloyl]-4-phenyl-1H-quinolin-2-one (Ceranib-2). Recrystallization from ethanol gave the target compound as off-white crystals in 89% yield with a melting point of 228°C to 230°C; Spectral data for Ceranib-2: 1H NMR δ 3.84 (s, 3H, OCH3), 6.67–6.70 (d, J = 15 Hz, 1H, HC), 6.87–6.89 (d, J = 10 Hz, 2H, Ar-H), 7.14–7.17 (m, 1H, Ar-H), 7.33–7.50 (m, 10H, Ar-H), 12.61 (s, 1H, NH);13C NMR δ 55.40, 114.34, 116.78, 120.01, 122.95, 125.54, 127.16, 127.56, 128.41, 128.80, 129.17, 130.28, 131.04, 131.41, 134.41, 138.40, 145.66, 150.26, 161.77, 193.83; MS m/z (relative intensity) 382.55 (M⁺ + 1, 100), 383.54(60). Cellular ceramidase assay

Ceramidase activity in human ovarian adenocarcinoma (SKOV3) cells more than 24 hours was measured using a previously described fluorogenic ceramidase substrate (38) according to our previously published protocol (39). Briefly, SKOV3 cells were grown to near confluence in 96-well plates, and then incubated with 16 μmol/L N-((2S,3R)-1,3-dihydroxy-5-(2-oxo-2H-chromen-7-yl)oxy)pentan-2-yl)palmitamide (ceramidase substrate) for 24 hours at 37°C. After incubation, the ceramidase cleavage product was converted to umbiliferone by adding 100 μL of 100% MeOH, 100 μL of NaIO4 (10 mg/mL in 100 mmol/L phosphate buffer pH 8.0) and...
50 µL of BSA (2 mg/mL in 100 mmol/L phosphate buffer pH 8.0) and incubating overnight at 37°C. The following day the samples were analyzed using a SpectraMax M5 platereader (Molecular Devices) at excitation and emission wavelengths of 355 and 460 nm, respectively. The relative fluorescent units for wells that did not contain cells were considered negative controls, and their values were subtracted from the values obtained from each of the wells containing cells.

**Cytotoxicity and cell proliferation assays**

The effects of the test compounds on SKOV3 cells were determined in 2 different treatment scenarios. The first was designed to replicate the exposures used in the ceramidase assay described above. In this method, SKOV3 cells at near-confluence were treated with DMSO, Ceranib-1 or Ceranib-2 at varying concentrations for 24 hours at 37°C. Subsequently, cell viability was determined using the MTS assay according to a standard protocol. The second treatment scenario involved exposure of sparsely plated SKOV3 cells to Ceranib-1 or Ceranib-2 alone or in combination with paclitaxel for 72 hours, followed by cell quantification using the sulforhodamine assay (40) to measure effects on cell proliferation. In either case, the percent cell survival was calculated as: \( \text{Survival} = \frac{A_{\text{experimental compound}}}{A_{\text{vehicle control}}} \times 100 \), and IC\text{50} values were determined for each compound alone by nonlinear regression analysis (GraphPad Prism 5.0). Combined drug effects were analyzed as isobolograms in which the line linking the doses for each compound alone by nonlinear regression analysis (GraphPad Prism 5.0). Combined drug effects were analyzed as isobolograms in which the line linking the combination of drugs is drawn. The area below the line indicates synergy, and points above the line indicate antagonism.

**Sphingolipid analyses**

Near-confluent SKOV3 cells were treated with DMSO, Ceranib-1 or Ceranib-2 at varying concentrations for 24 hours at 37°C. The cells were harvested, washed 3× with PBS and submitted to the Lipidomics Shared Facility Analytical Core of the Medical University of South Carolina for determination of sphingolipid and dihydrosphingolipid species by LC-MS/MS. The amounts of each lipid were normalized to phosphate levels in each biological sample, and the level of each sphingolipid was then expressed relative to levels in vehicle-treated cells, such that a value of 100% equals the level found in the controls.

**Cell-cycle analyses**

SKOV3 cells in exponential growth were treated with DMSO, 0.75 µmol/L, or 1.5 µmol/L Ceranib-2 for 48 hours at 37°C. The cells were then fixed in PBS:EtOH (1:3) at 4°C for 90 minutes, washed with PBS, and stained with PBS containing 20 µg/mL propidium iodide (Molecular Probes, P3566) and RNase A (Invitrogen, 12991-039) for 30 minutes at 37°C. Stained cells were analyzed on a FACSCalibur flow cytometer (BD Biosciences) at an excitation of 488 nm and emission of 585 nm. The number of cells emitting a given amount of fluorescence was plotted on histograms, and the percent of cells falling into each phase of the cell cycle was calculated. Histograms shown are representative of 2 experiments carried out in duplicate, and the values noted in the text represent the mean ± SEM of the percent of cells in each phase of the cell cycle.

**In vivo antitumor assay**

JC murine mammary adenocarcinoma cells (10⁶ cells in 100 µL PBS) were subcutaneously injected into the right flank of female Balb/c mice. Palpable tumors were apparent in 2 weeks, and the mice were randomized into 3 groups (n = 12–13) and treated with 0 [vehicle = PEG: DMSO (1:1)], 20 or 50 mg/kg of Ceranib-2. Treatments were administered by intraperitoneal injection daily for 5 days per week, and body weight and tumor size were measured twice per week. The volume of each tumor was calculated using the equation: Tumor volume = (Tumor length × Tumor width²)/2, and was expressed relative to treatment day 1 for each animal. Statistical significance was assessed by unpaired Student t test, with P ≤ 0.05 considered to be significant.

**Pharmacokinetic assays**

Female Balb/c mice (6–8 weeks old) were administered a dose of 50 mg/kg Ceranib-2 by intraperitoneal injection, and blood was harvested into EDTA-containing syringes by cardiac puncture at 0.5, 2, or 6 hours (n = 5/group). Plasma samples were prepared by centrifugation for 10 minutes at 4°C, and 0.1 mL of plasma was extracted twice with 1 mL of ethyl acetate. The combined organic extracts were dried under nitrogen at 35°C and dissolved in 65 µL of Solvent A (0.1% formic acid in MeOH). The samples were fractionated by reverse-phase HPLC on a Supelco Discovery C18 column (20 × 2.1 mm) using a linear gradient beginning with 30% Solvent A and 70% Solvent B (5% acetonitrile and 0.1% formic acid in water) and ending with 100% Solvent B more than 9 minutes at a flow rate of 0.4 mL/min. Ceranib-2 eluted at approximately 10.2 minutes, and was quantified by measuring its absorbance at 341 nm using a calibration curve of pure Ceranib-2.

**Results**

**Screen for inhibitors of human ceramidase activity**

A ceramide analogue that generates a fluorescent product following cleavage by ceramidase (38) was used to screen a ChemBridge DIVERset library consisting of approximately 50,000 drug-like compounds. SKOV3 cells were exposed to pools of 10 compounds (each at a final concentration of 30 µmol/L) and incubated with the fluorescent ceramide overnight. Ceramidase activity was measured as the increase in fluorescence as previously described (39). This assay was found to have an average Z-factor of 0.71, indicating that it is suitable for screening for ceramidase inhibitors. Compound pools...
that inhibited ceramidase activity were deconvoluted to identify individual active compounds, which were defined as those that reduced ceramidase activity by at least 75% at 100 μmol/L. This criterion was satisfied by only 0.03% of the screened compounds, and the 3-phenylacryloyl-4-phenyl-1H-quinolin-2-one scaffold was identified in multiple screening hits. The most active compound in the screening set was designated as Cerenib-1 (Fig. 1A), and chemical optimization was initiated (to be reported in detail elsewhere) that provided Cerenib-2 (Fig. 1B).

**Inhibition of ceramidase activity by Cerenib-1 and Cerenib-2**

To determine the potencies of Cerenib-1 and Cerenib-2 for inhibition of cellular ceramidase activity, SKOV3 cells at near-confluence were treated with varying concentrations of each for 24 hours. Subsequently, increased fluorescence produced by the hydrolysis of a fluorogenic ceramidase substrate by cellular ceramidase enzymes was measured. As shown in Fig. 2A, both compounds produce a dose-dependent decrease in ceramidase activity, with 50% inhibition at 55 and 28 μmol/L for Cerenib-1 and Cerenib-2, respectively. To ensure that the decreases in ceramidase activity were not caused by toxicity to the cells in this timeframe, SKOV3 cells in identical culture conditions were treated with Cerenib-1 or Cerenib-2 for 24 hours and the metabolic viability of the cells was determined using the MTS assay. As shown in Fig. 2B, neither compound caused significant cytotoxicity at concentrations up to at least those used in the ceramidase assay, indicating that the reduction in activity observed is not due to cell death. To compare the potency of our new compounds to previously described ceramidase inhibitors, we treated SKOV3 cells with DMAPP or N-oleoyl ethanolamine. DMAPP had no effect on ceramidase activity or cell survival up to at least 300 μmol/L, whereas N-oleoyl ethanolamine had no effect on ceramidase activity in this assay but did induce cell death with an IC50 of 50 ± 16 μmol/L. Therefore, the Cerenibs are considerably more potent than these lipid analogues for inhibiting ceramidase activity in an intact cell.

To determine whether the compounds are able to inhibit the hydrolysis of endogenous ceramides, SKOV3 cells at near-confluence were treated with Cerenib-1 or Cerenib-2 for 24 hours and the levels of intracellular sphingolipid and dihydrosphingolipid species were quantified by HPLC-mass spectrometry. As indicated in Fig. 3A, treatment with 12.5 μmol/L Cerenib-1 induced an accumulation of ceramide species including C16:0, C24:0, C26:0, and C26:1, with an overall increase of approximately 32% in total ceramide levels compared with vehicle-treated cells. In addition, Cerenib-1 induced a dose-dependent decrease in the intracellular levels of both sphingosine and S1P to 10 and 34% of vehicle-treated cells, respectively. Concerning the dihydrosphingosine species, Fig. 3C shows that Cerenib-1 had no effect on the levels of these lipids until a concentration of 50 μmol/L, at which point the levels of dhC16-Cer and dhS1P increased to approximately 650 and 3,000% of that observed in vehicle-treated cells, respectively. In contrast, as shown in Fig. 3B, Cerenib-2 induced an increase in the levels of every ceramide species measured, except C22 ceramide, with an increase in total ceramide levels approximately 109% greater than vehicle-treated cells at 3.125 μmol/L. Like Cerenib-1, Cerenib-2 caused a dose-dependent decrease in the intracellular levels of sphingosine and S1P to 16 and 30% of vehicle-treated cells, respectively. Also, as seen in Fig. 3D, Cerenib-2 caused an increase in the levels of dhC16-Cer at every concentration tested, reaching a peak of approximately 800% of that found in vehicle-treated cells at 50 μmol/L Cerenib-2. In contrast, this compound did not cause a large elevation in the levels of dhS1P, and induced a decrease of intracellular dhSph. Overall, these data suggest that the compounds prevent the hydrolysis of cellular ceramidase activity and acute cytotoxicity of ceramidase inhibitors. A, near-confluent SKOV3 cells were incubated in media containing 16 μmol/L, fluorogenic ceramidase substrate and DMSO (vehicle control), Cerenib-1 (●) or Cerenib-2 (■) at the indicated concentrations for 24 hours at 37°C. Hydrolysis of the ceramidase substrate was analyzed on a SpectraMax plate reader by measuring the increase in fluorescence at Excitation = 355 nm, Emission = 460 nm. B, SKOV3 cells at near-confluence were treated with DMSO, Cerenib-1 (●), or Cerenib-2 (■) at the indicated concentrations for 24 hours at 37°C. Cell viability was determined by the MTS assay. The values represent the mean ± SEM of 3 experiments carried out in triplicate.
of endogenous ceramide species and reduce intracellular sphingosine and S1P.

**Antiproliferative effects of Ceranib-1 and Ceranib-2**

To examine the effects of these compounds on cell proliferation, SKOV3 cells in exponential growth were treated with a ceramidase inhibitor for 72 hours and then the cell number was quantified. As shown in Fig. 4A, cell proliferation and/or survival were inhibited with IC50 values of 3.9 \( /C_6\) 0.3 and 0.73 \( /C_6\) 0.03 mmol/L for Ceranib-1 and Ceranib-2, respectively. In contrast, DMAPP did not inhibit cell proliferation to doses of at least 100 \( /C_6\) mmol/L, and \( /N\)-oleoylethanolamine showed an IC50 of approximately 60 \( /C_6\) mmol/L (data not shown).

Therefore, the increased potencies of the Ceranibs for inhibition of cell proliferation are consistent with their increased potencies for inhibiting cellular ceramidase activity.

Because SKOV3 cells are an ovarian adenocarcinoma cell line, we sought to determine whether these ceramidase inhibitors could be effectively combined with paclitaxel, a standard drug for ovarian cancer. As shown in Fig. 4B and C, paclitaxel inhibited SKOV3 proliferation with an IC50 of 2.60 \( /C_6\) 0.24 nmol/L, whereas single-agent Ceranib-1 and Ceranib-2 showed IC50s of 4.10 \( /C_6\) 0.42 and 0.71 \( /C_6\) 0.08 mmol/L, respectively. When used in combination, paclitaxel and Ceranib-1 or Ceranib-2 had additive effects on SKOV3 proliferation.

To determine the effects of Ceranib-2 on the cell cycle, SKOV3 cells in exponential growth were treated with DMSO, 0.75 \( /C_6\) 0.15 or 1.5 \( /C_6\) mmol/L Ceranib-2 for 48 hours. The cells were fixed, stained with PI, and the DNA content of each cell was measured by flow cytometry. As indicated in Fig. 5A, 45.52 \( /C_6\) 1.67, 28.58 \( /C_6\) 1.02, 25.90 \( /C_6\) 2.68, and 0.25 \( /C_6\) 0.07% of vehicle-treated cells were found to be in G1, S, G2, and sub-G1, respectively. In contrast, Fig. 5B shows that incubation of SKOV3 cells with 0.75 \( /C_6\) mmol/L Ceranib-2 changed the distribution of cells to 25.42 \( /C_6\) 0.68, 41.36 \( /C_6\) 3.54, 33.23 \( /C_6\) 4.22, and 11.38 \( /C_6\) 3.37% in G1, S, G2, and sub-G1, respectively. A higher dose of Ceranib-2 (1.5 \( /C_6\) mmol/L, Fig. 5C) further altered the cell-cycle distribution to 22.53 \( /C_6\) 0.17, 29.90 \( /C_6\) 2.75, 47.57 \( /C_6\) 2.58, and 15.82 \( /C_6\) 3.30% in G1, S, G2, and sub-G1. Overall, these data indicate that Ceranib-2 causes accumulation of...
Antitumor activity of Ceranib-2

To determine whether the novel ceramidase inhibitor has antitumor activity, a syngeneic tumor model consisting of JC mammary adenocarcinoma cells growing subcutaneously in immunocompetent Balb/c mice was used. When palpable tumors were observed, mice were randomized into groups \((n = 12-13)\) receiving 0, 20, or 50 mg/kg Ceranib-2 by intraperitoneal injection on 5 days per week. As indicated in Fig. 6A, the average normalized size of tumors in each treatment group increased over time. However, by day 11 both Ceranib-2-treated groups had significantly lower tumor volumes than did the vehicle-treated controls. By day 21, the average normalized tumor volumes for the control, 20 mg/kg and 50 mg/kg Ceranib-2 groups were 1,400 ± 370, 940 ± 290, and 710 ± 170\% respectively. Administration of Ceranib-2 did not affect the total body weight of the animals (insert in Fig. 6A). Also, blood samples from 3 representative mice of each group were assessed for blood chemistry and complete blood cell counts, and all groups were statistically equivalent (data not shown). Finally, in preliminary pharmacokinetic evaluations (Fig. 6B), intraperitoneal administration of 50 mg/kg Ceranib-2 resulted in progressive increases in its circulating levels, reaching a peak plasma concentration of approximately 40 µmol/L at the 2-hour time point. This concentration of Ceranib-2 is well above that required to inhibit cell proliferation; however, the compound seems to be cleared with a half-life of less than 2 hours.

Discussion

To identify inhibitors of ceramidase activity with more favorable "drug-like" properties than existing compounds, a high-throughput screen was developed in SKOV3 cells using a previously described fluorogenic ceramidase assay (39), and approximately 50,000 compounds from the ChemBridge DIVERset Library were screened. Ceranib-1 emerged from the screen as a lead compound, and several analogues were synthesized to begin the assessment of structure-activity relationships. Ceranib-2 was found to be the most potent inhibitor in the cell-based assay with an IC\(_{50}\) of 28 µmol/L compared with 55 µmol/L for Ceranib-1.

Although this data provided a strong indication that the compounds inhibit intracellular ceramidase activity in SKOV3 cells, it was necessary to rule out the potential that these results represented a false positive due to cell death induced by the compounds. To study this, SKOV3 cells under the same conditions as those in the high-throughput screen were assessed for metabolic activity using the MTS assay to determine cell viability. Neither compound induced significant cell death under the same conditions as those in the high-throughput screen, indicating that the inhibition of ceramidase activity observed upon treatment with the compounds was not simply due to cell death. In contrast, DMAPP did not decrease cellular ceramidase activity or cell viability at up to at least 300

![Image 1](https://example.com/image1.png)

![Image 2](https://example.com/image2.png)

![Image 3](https://example.com/image3.png)

Figure 4. Cytotoxicities of Ceranibs alone and in combination with paclitaxel. A, SKOV3 cells in exponential growth were treated with varying concentrations of Ceranib-1 or Ceranib-2 for 72 hours at 37°C, and cell numbers were quantified using the SRB assay. The values represent the mean ± SEM of 3 experiments carried out in triplicate. B, SKOV3 cells in exponential growth were treated with paclitaxel alone, Ceranib-1 alone, or paclitaxel in combination with Ceranib-1 for 72 hours at 37°C. C, SKOV3 cells in exponential growth were treated with paclitaxel alone, Ceranib-2, or paclitaxel in combination with Ceranib-2 for 72 hours at 37°C. Cell survival was determined by SRB assay. In B and C, isobolograms were constructed to show the combined effects of paclitaxel and Ceranib-1 or Ceranib-2. The line of additivity connects the single-agent IC\(_{50}\)s for the test compounds, and values represent the mean ± SEM of 6 experiments carried out in triplicate.

cells in the sub-G\(_1\) (apoptosis), G\(_2\), and S (0.75 µmol/L only) phases of the cell cycle, concomitant with reductions in the number of cells in G\(_1\) phase.
Both compounds produced a substantial decrease in the number of cells; however, Ceranib-2 was approximately 5 times more potent than Ceranib-1 with IC_{50} values of 0.73 and 3.92 μmol/L, respectively. There are 2 potential explanations for this difference in potency compared with the cell-based ceramidase activity assay. First, the ceramide/S1P rheostat model dictates that as the balance shifts in the direction of greater total ceramides and lower S1P cells undergo apoptosis. Thus, because lower concentrations of Ceranib-2 cause a greater accumulation of total ceramides than Ceranib-1, Ceranib-2 causes a shift in the rheostat at lower concentrations leading to cell death. Second, Ceranib-1 greatly increases the levels of intracellular dhS1P, whereas Ceranib-2 does not. DhSIP is known to activate the ERK signaling pathway, which stimulates survival and proliferation (41). It should also be noted that both compounds induce an accumulation of the antiapoptotic species dhC_{16}-Cer, which has been shown to inhibit ceramide channel formation in the mitochondria, decreasing permeabilization of the membrane, blocking apoptosis (42). However, the increase in this ceramide species may simply be a survival response to the increase in proapoptotic ceramide species.

The fluorogenic ceramide analogue used on our studies is a direct analogue of saturated dhC_{16}-Cer. Therefore, the cellular ceramidase assay is specifically measuring the activity of ceramidases that hydrolyze dhC_{16}-Cer. Previous studies have shown that acid and neutral ceramidase have activity toward this substrate (43–44). In contrast, the alkaline ceramidases have not been reported to have activity toward this specific substrate (45, 46). Therefore, it seems likely that the fluorogenic cellular assay is measuring the activity of acid and neutral ceramidases; however, we cannot conclude that our compounds only inhibit these 2 enzymes. In addition, while the ceramide isozymes show substrate specificity, there is considerable overlap among the isozymes. In particular, alkaline ceramidase 2 has a very broad range of

![Cells cycle effects of Ceranib-2](image-url)
substrate specificity, with activity toward ceramide species from C2 to C24 (47). Therefore, we cannot attribute the observed accumulation of ceramide species to the inhibition of any one particular ceramidase enzyme. Further studies are in progress to determine whether Ceranib-1 and Ceranib-2 are selective or paninhibitory toward the ceramidases.

Ceramides have been shown to regulate the sensitivity of tumor cells to anticancer drugs (48, 49), including paclitaxel (21). Our data show that coadministration of Ceranib-1 or Ceranib-2 with paclitaxel leads to additive inhibition of proliferation of SKOV3 cells. Although synergy was not observed under these conditions, we will continue to assess the combined effects of new Ceranib analogues with established and experimental anticancer drugs. Exposure of cells to Ceranib-2 caused an accumulation in the G2 phase of the cell cycle and promoted apoptosis. This is consistent with a previous report of quinolinones with similar structures to the Ceranibs that are reported to induce caspase activation (50). The ability of Ceranib-2 to induce apoptosis and cause arrest in the G2–M phase likely contributes to the additivity seen with the microtubule stabilizer paclitaxel, which also causes arrest in the G2–M phase. Overall, these data show that Ceranib-2 is both antiproliferative and cytotoxic to ovarian cancer cells.

To determine whether Ceranib-2 has in vivo effects on tumor growth, Balb/c mice were subcutaneously injected with JC cells, allowed to develop palpable tumors, and treated intraperitoneally with 0, 20, or 50 mg/kg Ceranib-2. This model was used to assess the effects of the compound in animals with a functional immune system. Ceranib-2 produced a dose-dependent suppression in tumor growth over time, with statistically significant differences in tumor volume occurring by day 11 of the study. By termination of the study on day 21, mice treated with 50 mg/kg Ceranib-2 had only half of the increase in tumor size observed in vehicle-treated mice, indicating that Ceranib-2 is able to suppress tumor growth in vivo. Total body weight of mice treated with Ceranib-2 did not change over time, and no significant difference was observed in the blood chemistry or blood cell counts among any group, suggesting low toxicity with repeated administration of the compound. The plasma concentration of Ceranib-2 peaked at approximately 40 µmol/L 2 hours after administration, and remained above the IC50 of the in vitro antiproliferative assays for approximately 6 hours. However, more robust studies will need to be undertaken to determine other pharmacokinetic parameters such as volume of distribution, clearance and half-life of the compound.

In conclusion, these studies characterize Ceranib-1 and Ceranib-2 as novel inhibitors of human ceramidase activity that may serve as a new chemotype for the development of anticancer therapeutics. These compounds are able to inhibit cellular ceramidase activity causing an accumulation of ceramides and a reduction in cellular sphingosine and S1P. These compounds were also found to inhibit cell proliferation and induce cell death in a human ovarian cancer cell line, both as single agents and in an additive manner with paclitaxel. In addition, administration of Ceranib-2 to tumor-bearing mice reduced tumor growth with no overt signs of toxicity with repeated treatment. Overall, these studies suggest that Ceranib-2 can serve as a lead compound in the development of a new class of anticancer therapeutics. In future studies, we will focus on identifying the specific ceramidase isozyme(s) affected, characterizing the signaling pathways disrupted by administration, and broaden the scope of the in vivo data to include multiple cancer models with pharmacokinetic and toxicology profiles.

Disclosure of Potential Conflicts of Interest

C.D. Smith is employed by and has ownership interest (including patents) in Apogee Biotechnology Corporation.
Grant Support

These studies used several shared resources funded in part by the Hollings Cancer Center, including the Drug Discovery Core, the Lipidomics Shared Facility Analytical Core, and the Flow Cytometry Core Facility. The study was financially supported by NIH grant 1 R01 CA122226 (C. D. Smith).

References


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 19, 2011; revised August 19, 2011; accepted August 23, 2011. published OnlineFirst September 1, 2011.


Molecular Cancer Therapeutics

Discovery and Evaluation of Inhibitors of Human Ceramidase

Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, et al.

Mol Cancer Ther 2011;10:2052-2061. Published OnlineFirst September 1, 2011.

Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-11-0365

This article cites 50 articles, 16 of which you can access for free at:
http://mct.aacrjournals.org/content/10/11/2052.full#ref-list-1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/10/11/2052.
Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.